EA202091590A1 - Антитела против pd-l1 и варианты их применения - Google Patents
Антитела против pd-l1 и варианты их примененияInfo
- Publication number
- EA202091590A1 EA202091590A1 EA202091590A EA202091590A EA202091590A1 EA 202091590 A1 EA202091590 A1 EA 202091590A1 EA 202091590 A EA202091590 A EA 202091590A EA 202091590 A EA202091590 A EA 202091590A EA 202091590 A1 EA202091590 A1 EA 202091590A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- seq
- fragments
- antibodies
- antibodies against
- application options
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Abstract
Предложены антитела против PD-L1 или их фрагменты. Указанные антитела или их фрагменты специфически связываются с иммуноглобулиновым С-доменом белка PD-L1. В различных примерах указанные антитела или их фрагменты включают VH CDR1 из SEQ ID NO: 1, VH CDR2 из SEQ ID NO: 116, VH CDR3 из SEQ ID NO: 117, VL CDR1 из SEQ ID NO: 4, VL CDR2 из SEQ ID NO: 5 и VL CDR3 из SEQ ID NO: 6 или варианты каждого из перечисленных. Также предложены способы применения указанных антител или их фрагментов для лечения и диагностики заболеваний, таких как рак и инфекционные заболевания.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018081079 | 2018-03-29 | ||
PCT/CN2019/080458 WO2019185029A1 (en) | 2018-03-29 | 2019-03-29 | Anti-pd-l1 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202091590A1 true EA202091590A1 (ru) | 2021-01-21 |
Family
ID=68060946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091590A EA202091590A1 (ru) | 2018-03-29 | 2019-03-29 | Антитела против pd-l1 и варианты их применения |
Country Status (18)
Country | Link |
---|---|
US (2) | US11220546B2 (ru) |
EP (1) | EP3589660A4 (ru) |
JP (1) | JP7124257B2 (ru) |
KR (2) | KR102475106B1 (ru) |
CN (1) | CN110891975B (ru) |
AU (1) | AU2019241339B2 (ru) |
BR (1) | BR112020019827A2 (ru) |
CA (1) | CA3086434C (ru) |
CL (1) | CL2020002223A1 (ru) |
EA (1) | EA202091590A1 (ru) |
IL (1) | IL275734B (ru) |
MX (1) | MX2020007842A (ru) |
MY (1) | MY188237A (ru) |
PE (1) | PE20210377A1 (ru) |
PH (1) | PH12020551173A1 (ru) |
SG (1) | SG11202006008WA (ru) |
UA (1) | UA125918C2 (ru) |
WO (1) | WO2019185029A1 (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018015584A (es) * | 2016-06-13 | 2019-09-18 | I Mab | Anticuerpos anti-pd-l1 y usos de los mismos. |
CN112041348B (zh) * | 2018-07-25 | 2023-09-22 | 天境生物科技(上海)有限公司 | 抗cd73抗pd-l1双特异性抗体 |
CA3109999A1 (en) * | 2018-08-21 | 2020-02-27 | Abl Bio Inc. | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof |
WO2021097800A1 (en) * | 2019-11-22 | 2021-05-27 | Abl Bio Inc. | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof |
WO2021219092A1 (en) * | 2020-04-30 | 2021-11-04 | I-Mab Biopharma Co., Ltd. | Pharmaceutical compositionscontaining anti-cd47 antibodies |
AU2021329378A1 (en) | 2020-08-19 | 2023-03-23 | Xencor, Inc. | Anti-CD28 compositions |
CN114195900B (zh) * | 2020-09-17 | 2024-02-23 | 普米斯生物技术(珠海)有限公司 | 一种抗4-1bb/pd-l1双特异性抗体及其用途 |
CN114316045A (zh) * | 2020-09-29 | 2022-04-12 | 锋宏生物医药科技(昆山)有限公司 | 抗pd-l1抗体及其用途 |
CN113234162B (zh) * | 2020-12-24 | 2022-05-13 | 四川大学华西医院 | 一种靶向cd133的嵌合抗原受体t细胞 |
WO2022148414A1 (zh) * | 2021-01-08 | 2022-07-14 | 北京韩美药品有限公司 | 特异性结合pd-l1的抗体及其抗原结合片段 |
TW202346366A (zh) * | 2022-04-02 | 2023-12-01 | 大陸商和鉑醫藥(上海)有限責任公司 | 標靶pd-l1和cd40的抗原結合蛋白及其製備和應用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2439273T (lt) * | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
WO2011043194A1 (en) | 2009-10-09 | 2011-04-14 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device and method for manufacturing the same |
JP6526189B2 (ja) * | 2014-07-03 | 2019-06-05 | ベイジーン リミテッド | 抗pd−l1抗体並びにその治療及び診断のための使用 |
BR112017010324A2 (pt) * | 2014-11-20 | 2018-05-15 | F. Hoffmann-La Roche Ag | método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula |
CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
MX2018015584A (es) * | 2016-06-13 | 2019-09-18 | I Mab | Anticuerpos anti-pd-l1 y usos de los mismos. |
CN107488229B (zh) | 2016-06-13 | 2020-11-17 | 天境生物科技(上海)有限公司 | Pd-l1抗体及其用途 |
CN108777906B (zh) | 2018-06-25 | 2020-06-16 | 珠海惠尔益电子科技有限公司 | 一种双灯组变焦电路及头灯 |
CN112041348B (zh) * | 2018-07-25 | 2023-09-22 | 天境生物科技(上海)有限公司 | 抗cd73抗pd-l1双特异性抗体 |
JP7328658B2 (ja) * | 2018-11-30 | 2023-08-17 | エービーエル バイオ インコーポレイテッド | 抗pd-l1/抗4-1bb二重特異性抗体およびその使用 |
-
2019
- 2019-03-29 US US16/610,071 patent/US11220546B2/en active Active
- 2019-03-29 KR KR1020207032104A patent/KR102475106B1/ko not_active Application Discontinuation
- 2019-03-29 CN CN201980003429.7A patent/CN110891975B/zh active Active
- 2019-03-29 MY MYPI2020003980A patent/MY188237A/en unknown
- 2019-03-29 AU AU2019241339A patent/AU2019241339B2/en active Active
- 2019-03-29 KR KR1020197031498A patent/KR102177931B1/ko active IP Right Grant
- 2019-03-29 SG SG11202006008WA patent/SG11202006008WA/en unknown
- 2019-03-29 EA EA202091590A patent/EA202091590A1/ru unknown
- 2019-03-29 JP JP2019553005A patent/JP7124257B2/ja active Active
- 2019-03-29 EP EP19769368.2A patent/EP3589660A4/en active Pending
- 2019-03-29 BR BR112020019827-7A patent/BR112020019827A2/pt unknown
- 2019-03-29 PE PE2020001301A patent/PE20210377A1/es unknown
- 2019-03-29 MX MX2020007842A patent/MX2020007842A/es unknown
- 2019-03-29 WO PCT/CN2019/080458 patent/WO2019185029A1/en unknown
- 2019-03-29 UA UAA202005634A patent/UA125918C2/uk unknown
- 2019-03-29 CA CA3086434A patent/CA3086434C/en active Active
-
2020
- 2020-06-29 IL IL275734A patent/IL275734B/en unknown
- 2020-08-02 PH PH12020551173A patent/PH12020551173A1/en unknown
- 2020-08-28 CL CL2020002223A patent/CL2020002223A1/es unknown
-
2021
- 2021-12-28 US US17/563,502 patent/US20220119531A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR102177931B1 (ko) | 2020-11-13 |
JP2020518233A (ja) | 2020-06-25 |
US11220546B2 (en) | 2022-01-11 |
EP3589660A1 (en) | 2020-01-08 |
IL275734A (en) | 2020-08-31 |
CL2020002223A1 (es) | 2021-01-29 |
KR20190128716A (ko) | 2019-11-18 |
AU2019241339B2 (en) | 2021-08-12 |
JP7124257B2 (ja) | 2022-08-24 |
US20200157222A1 (en) | 2020-05-21 |
KR20200130747A (ko) | 2020-11-19 |
UA125918C2 (uk) | 2022-07-06 |
IL275734B (en) | 2022-06-01 |
US20220119531A1 (en) | 2022-04-21 |
EP3589660A4 (en) | 2021-04-07 |
MY188237A (en) | 2021-11-24 |
CN110891975B (zh) | 2023-11-10 |
AU2019241339A1 (en) | 2019-11-14 |
PH12020551173A1 (en) | 2021-05-31 |
MX2020007842A (es) | 2020-09-25 |
BR112020019827A2 (pt) | 2021-01-05 |
CA3086434A1 (en) | 2019-10-03 |
KR102475106B1 (ko) | 2022-12-08 |
WO2019185029A1 (en) | 2019-10-03 |
SG11202006008WA (en) | 2020-07-29 |
CA3086434C (en) | 2024-01-09 |
PE20210377A1 (es) | 2021-03-02 |
CN110891975A (zh) | 2020-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
MY190771A (en) | Anti-pd-l1 antibodies and uses thereof | |
EA201991099A1 (ru) | Антитела против cd73 и их применение | |
AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
JP2019535763A5 (ru) | ||
IL299221A (en) | CD3 binding antibodies | |
NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
JP2018527919A5 (ru) | ||
AR109715A1 (es) | Anticuerpos anti-cd27 | |
RU2016129517A (ru) | Биспецифические антитела к her2 и способы применения | |
NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
RU2016100892A (ru) | Антитела против tweakr и их применение | |
MA40913A (fr) | Conjugués anticorps-médicament | |
UA115781C2 (uk) | Cx3cr1-зв'язуючий поліпептид | |
JP2016502515A5 (ru) | ||
JP2016530223A5 (ru) | ||
WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
WO2015161267A3 (en) | Humanized and chimeric monoclonal antibodies to cd99 | |
EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
RU2018121413A (ru) | Антитело ANTI-PCSK9 и его применение | |
EA202190495A1 (ru) | Антитела против pd-l1 человека | |
PE20190633A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos |